Patents Assigned to St. Pharm Co., Ltd.
-
Publication number: 20230382943Abstract: The present invention relates to a novel oligonucleotide primer used for the synthesis of 5?-capped RNA. The novel oligonucleotide primer for RNA capping provided as Formula 1 in the present invention can be usefully utilized in the fields of nucleic acid therapeutic agents or vaccines.Type: ApplicationFiled: October 19, 2021Publication date: November 30, 2023Applicant: ST PHARM CO., LTD.Inventors: Kyung Jin Kim, Kang Hyun Choi, Uk-Il Kim, Hyung Tae Bang, Seul Ki Lee, Si Yeon Han
-
Publication number: 20230373994Abstract: The present invention relates to a pyrrolopyridine derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and use thereof. The compound of the present invention has high selectivity and bioactivity against human immunodeficiency virus (HIV), and low toxicity, thus being useful as a therapeutic agent for viral infection, particularly human immunodeficiency virus (HIV) infection.Type: ApplicationFiled: August 20, 2021Publication date: November 23, 2023Applicant: ST PHARM CO., LTD.Inventors: Kyungjin Kim, Uk-Il Kim, Hyung Tae Bang, Seul Ki Lee, Si Yeon Han
-
Patent number: 11655268Abstract: The present disclosure relates to a novel nucleoside or nucleotide derivative, a racemate thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating viral infection-associated diseases, containing the same as an active ingredient.Type: GrantFiled: January 24, 2019Date of Patent: May 23, 2023Assignee: ST PHARM CO., LTD.Inventors: Kyungjin Kim, Meehyein Kim, Uk-Il Kim, Yun Young Go, Hwajung Nam, Hyung Tae Bang, Jin Soo Shin, Jihye Yoon, Yejin Jang
-
Publication number: 20220235011Abstract: Provided is a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, including as an active ingredient, a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases including administering a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof to a subject in need.Type: ApplicationFiled: May 29, 2020Publication date: July 28, 2022Applicants: ST PHARM CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyungjin KIM, Kwangrok KIM, Uk-Il KIM, Hyung Tae BANG, Seul Ki LEE, Kwan-Young JEONG, Seung Kyu KANG, Heejung JUNG, Sang Dal RHEE, Won Hoon JUNG, Jun Mi LEE
-
Patent number: 11214570Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.Type: GrantFiled: March 24, 2017Date of Patent: January 4, 2022Assignee: ST PHARM CO., LTD.Inventors: Bong Jin Kim, Ill Young Lee, Jae Hak Kim, Hong Suk Shin, Jong Chan Son, Chong-Kyo Lee, Kyungjin Kim, Uk-Il Kim, Hwa Jung Nam
-
Patent number: 11149033Abstract: The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.Type: GrantFiled: September 29, 2017Date of Patent: October 19, 2021Assignees: INSTITUT PASTEUR KOREA, ST PHARM CO., LTD.Inventors: Ji Young Min, So Young Chang, Ji Hye Lee, Sun Hee Kang, Sun Ju Kong, Su Yeon Jo, Young Mi Kim, Junghwan Choi
-
Patent number: 11059852Abstract: The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.Type: GrantFiled: July 22, 2019Date of Patent: July 13, 2021Assignee: ST PHARM CO., LTD.Inventors: Hakwon Kim, Tae Hoon Lee, Hoongyu Park, Hyunjeong Oh
-
Publication number: 20200377498Abstract: Provided is a novel pyrrolopyridine compound represented by Chemical Formula I, a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and to a method for preparing the same. A compound represented by Chemical Formula I shows high selectivity and antiviral activity against human immunodeficiency virus (HIV), with low toxicity; therefore, it is useful as a therapeutic agent for viral infection, in particular, HIV infection.Type: ApplicationFiled: March 24, 2017Publication date: December 3, 2020Applicant: ST PHARM CO., LTD.Inventors: Bong Jin KIM, Ill Young LEE, Jae Hak KIM, Hong Suk SHIN, Jong Chan SON, Chong-Kyo LEE, Kyungjin KIM, Uk-Il KIM, Hwa Jung NAM
-
Patent number: 10702546Abstract: The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using saidType: GrantFiled: November 29, 2012Date of Patent: July 7, 2020Assignee: ST PHARM CO., LTD.Inventors: Young Ro Byun, Al-Hilal Taslim Ahmed, Ok Cheol Jeon, Hyun Tae Moon, Kyungjin Kim, Jisuk Yun
-
Patent number: 10702859Abstract: The present disclosure provides a method for preparing ((2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene))bis(bis(2-methoxyphenyl)phosphine), a ligand for a polyketone polymerization catalyst, under mild conditions with high purity and high yield. Therefore, the preparation method of the present disclosure can be easily applied to mass production.Type: GrantFiled: November 11, 2016Date of Patent: July 7, 2020Assignee: ST PHARM CO., LTD.Inventors: Geun Jho Lim, Sun Ki Chang, Hyun Woo Baek, Jun Hyun Oh, Yeong Hun Kim
-
Patent number: 10538504Abstract: Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency under optimal processing conditions and making it suitable for industrial mass production.Type: GrantFiled: December 9, 2016Date of Patent: January 21, 2020Assignee: ST PHARM CO., LTD.Inventors: Seok Hun Woo, YunHee Choi, Hong Jun Kim, Sun Ki Chang, Geun Jho Lim
-
Patent number: 10501403Abstract: The present invention relates to a novel method for preparing (S)—N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride.Type: GrantFiled: November 3, 2017Date of Patent: December 10, 2019Assignee: ST PHARM CO., LTD.Inventors: Yeong Hun Kim, Hyun Woo Baek, Hyeon Jin Lee, Sang Kyu Kang, Sun Ki Chang, Geun Jho Lim
-
Publication number: 20190337976Abstract: The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.Type: ApplicationFiled: July 22, 2019Publication date: November 7, 2019Applicant: ST PHARM CO., LTD.Inventors: Hakwon KIM, Tae Hoon LEE, Hoongyu PARK, Hyunjeong OH
-
Patent number: 10428096Abstract: Provided are a novel polyketone polymerization catalyst and a method of preparing a ligand, which can reduce production costs and can enable commercial mass synthesis by using ((2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene))bis(bis(2-methoxyphenyl)phosphine) as a ligand constituting the polykeytone polymerization catalyst, the ligand having a simple structure and a small molecular weight while having high activity.Type: GrantFiled: July 16, 2014Date of Patent: October 1, 2019Assignees: HYOSUNG CHEMICAL CORPORATION, ST PHARM CO., LTD.Inventors: Jae Yoon Shim, Sun Kue Kim, Hae Souk Cho, Ji Hwan Choi, Geun Jho Lim, Sun Ki Chang, Min Kyu Kim, In Hyeok Baek
-
Patent number: 10336765Abstract: The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: GrantFiled: December 1, 2016Date of Patent: July 2, 2019Assignee: ST. PHARM CO., LTD.Inventors: Kyungjin Kim, Uk-Il Kim, Ji Hye Yoon
-
Patent number: 10179785Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: GrantFiled: July 10, 2015Date of Patent: January 15, 2019Assignee: ST PHARM CO., LTD.Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
-
Patent number: 10065933Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.Type: GrantFiled: December 28, 2015Date of Patent: September 4, 2018Assignee: ST PHARM CO., LTD.Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim
-
Patent number: 9914737Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: GrantFiled: July 10, 2015Date of Patent: March 13, 2018Assignee: ST PHARM CO., LTD.Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
-
Publication number: 20170342038Abstract: The present disclosure relates to a novel method for preparing high-purity gadobutrol. The present disclosure can be easily applied to a large scale production because purity of intermediate can be managed via simple and mild process and accordingly, high-purity or ultra high-purity gadobutrol that has higher purity than previous gadobutrol can be prepared in high yield therethrough.Type: ApplicationFiled: December 28, 2015Publication date: November 30, 2017Applicant: ST PHARM CO., LTD.Inventors: Geun Jho LIM, Sun Ki CHANG, Chang Ho BYEON, Hoe Jin YOON, Moon Soo Kim
-
Patent number: 9822084Abstract: Disclosed is a novel method of preparing highly pure calcobutrol using an intermediate (butrol) of gadobutrol without using highly pure gadobutrol. This method is capable of obtaining calcobutrol at high purity and high yield through a simple and environmentally friendly process, and thus can be easily applied to mass production.Type: GrantFiled: September 7, 2015Date of Patent: November 21, 2017Assignee: ST PHARM CO., LTD.Inventors: Geun Jho Lim, Sun Ki Chang, Chang Ho Byeon, Hoe Jin Yoon, Moon Soo Kim